Invivyd Announces $20 Million to $25 Million Improvement in Projected 2024 Year-End Cash Position
April 30, 2024 07:30 ET
|
Invivyd
Improvements realized through comprehensive resource realignment ensuring robust investment in the commercial launch of PEMGARDATM and the discovery of novel monoclonal antibodiesCompany now expects...
Invivyd Receives Healthcare Common Procedure Coding System (HCPCS) Reimbursement Codes from the U.S. Centers for Medicare & Medicaid Services (CMS) Covering PEMGARDA™
April 15, 2024 07:30 ET
|
Invivyd
Invivyd Receives HCPCS Reimbursement Codes from the U.S. Centers for Medicare & Medicaid Services (CMS) covering PEMGARDA
Invivyd Announces CEO Transition
April 12, 2024 07:30 ET
|
Invivyd
WALTHAM, Mass., April 12, 2024 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a biopharmaceutical company on a mission to protect the vulnerable from serious viral infectious diseases, today...
Invivyd Provides PEMGARDA™ Launch Update and Announces 2024 Net Product Revenue Guidance in the Range of $150 Million to $200 Million
April 04, 2024 16:01 ET
|
Invivyd
PEMGARDA now commercially available in the U.S. for pre-exposure prophylaxis (PrEP) of COVID-19 in certain adults and adolescents with moderate-to-severe immune compromise Based on anticipated net...
Invivyd Reports Full Year 2023 Financial Results and Recent Business Highlights
March 28, 2024 07:00 ET
|
Invivyd
Received emergency use authorization for PEMGARDA™, a monoclonal antibody (mAb) authorized in the U.S. for pre-exposure prophylaxis (PrEP) of COVID-19 in certain adults and adolescents with...
Invivyd Announces Interim Exploratory Data on VYD222 from Ongoing CANOPY Clinical Trial
March 22, 2024 15:28 ET
|
Invivyd
Analysis of secondary endpoint of symptomatic COVID-19 events in CANOPY is unrelated to regulatory filing or review, but may be hypothesis generating for future Invivyd discovery and development...
Invivyd Announces FDA Authorization for Emergency Use of PEMGARDA™ (Formerly VYD222) for Pre-exposure Prophylaxis (PrEP) of COVID-19
March 22, 2024 15:04 ET
|
Invivyd
PEMGARDA (pemivibart) is authorized in the U.S. for PrEP of COVID-19 in certain adults and adolescents with moderate-to-severe immune compromise Emergency use authorization based on positive...
Invivyd to Participate at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
February 05, 2024 16:02 ET
|
Invivyd
WALTHAM, Mass., Feb. 05, 2024 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a biopharmaceutical company on a mission to protect the vulnerable from serious viral infectious diseases, today...
Invivyd Submits Request for Emergency Use Authorization (EUA) to U.S. FDA for VYD222 for the Pre-exposure Prevention of COVID-19 in Immunocompromised Adults and Adolescents
January 03, 2024 07:00 ET
|
Invivyd
EUA submission is based on positive initial results from the ongoing CANOPY Phase 3 pivotal clinical trial and ongoing in vitro neutralization activity against relevant SARS-CoV-2 variantsVYD222...
Invivyd Announces Positive Initial Results from Ongoing CANOPY Phase 3 Pivotal Clinical Trial Investigating VYD222 for the Prevention of COVID-19
December 18, 2023 07:00 ET
|
Invivyd
Invivyd Announces Positive Initial Results from Ongoing CANOPY Phase 3 Pivotal Clinical Trial Investigating VYD222 for the Prevention of COVID-19